The dexamethasone suppression test and antidepressant response in major depression

Jeffrey S. Simon, Dwight Landis Evans, Charles B. Nemeroff

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


We conducted a prospective open pilot study of 34 consecutively admitted patients with the DSM-III diagnosis of MD who were admitted to a general psychiatric unit. Patients underwent a 1 mg DST and were randomly assigned to treatment with either maprotiline or trazodone. Antidepressant dosages were increased as tolerated clinically and according to treatment response. Results: mean final oral doses were 193 mg for maprotiline and 328 mg for trazodone. The mean treatment duration was 4.5 weeks for maprotiline and 5.9 weeks for the trazodone group. Of these 34 patients 44% showed DST nonsuppression (41% maprotiline, 45% trazodone).Seventy-six per cent of the patients responded to treatment (76% for both drugs) as defined by GAS. Eighty-seven per cent of the nonsuppressors responded to treatment (86% maprotiline, 88% trazodone) and 68% of the suppressors responded (70% maprotiline, 67% trazodone). Of the eight treatment non-responders six showed DST suppression. The implications of these findings are discussed.

Original languageEnglish (US)
Pages (from-to)313-317
Number of pages5
JournalJournal of Psychiatric Research
Issue number3
StatePublished - 1987
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'The dexamethasone suppression test and antidepressant response in major depression'. Together they form a unique fingerprint.

Cite this